Invest Now
Amazing investment opportunity. A top pick for 2021.

Changing the landscape of neurological diagnostics for clinical, emergency, and ambulatory applications. Brain Scientific has made electroencephalogram (EEG) technology widely available across the globe through revolutionary new products and technology.

Invest in the future of neurology with Brain Scientific and play a part in not only making neurological care accessible to everyone, but improve healthcare outcomes through predictive algorithms for epilepsy, Alzheimer’s, and Parkinson’s disease.

Invest Now
  • Leverages AI and machine learning to improve diagnosis of complex cases
  • Enables brain-computer interfaces
  • Disposable to eliminate any chance of infection
  • Quick and easy to set up, train technicians & administer to patients
  • FDA cleared
How It Works
decor image
Solving Major Medical Challenges On A Global Scale
icon
Only 30% of US hospitals have equipment for routine EEGs due to cost and space
icon
Several “neurology deserts” exist in the US and availability outside the country is even more
icon
Approximately 5MM ER patients are indicated for an EEG each year, yet only 25% receive one
icon
Traditional EEG systems are bulky, require dedicated technicians to administer, can take 30 minutes to apply, and require an in-house neurologist to read
icon
Reusable EEG caps are a significant source of hospital acquired infections
Brain E-Tattoo: Revolutionary, Nobel Prize Winning Technology by Brain Scientific

Brain Scientific has commenced development of its proposed Brain E-Tattoo device for the brain diagnostics market, which is expected to feature minimally invasive, subcutaneous graphene electrode implants paired with a micro EEG. The proposed Brain E-Tattoo device is expected to allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions such as epilepsy, Alzheimer’s disease, stroke, and other brain disorders.

It works via a graphene based electrode system connected to a micro EEG that is clipped behind the ear. The micro EEG processes signals collected by the sensors and wirelessly and securely stores them in the cloud, where AI performs continuous analysis.

What is Graphene?
  • Highly conductive, very strong yet flexible, & ultra-thin (5-10 times thinner than a human hair)
  • Minimally invasive (can be placed under the skin or over it, depending on the application)
  • Significantly more sensitive than platinum (and cheaper)
  • Non-toxic & fully bio-compatible

 

The Brain E-Tattoo advancement is applicable for studying and treating Epilepsy, Alzheimer’s disease, stroke and other brain disorders. The involvement of AI is leading us towards being able to better understand brain signals and predict abnormal activity.

Invest Now
img
Take Part in a Big Opportunity
ER Indications for Routine EEC
Indication
#Of Admissions
Altered Mental Status
2,738,000
Seizure
1,370,000
Stroke
795,000
Total
4,903,000
Total Addressable Market
$ 534,427,000
img
img
Total Addressable Market
$534MM
Emergency Departments
$1.1B
Emergency Departments
$4.8B
Emergency Departments
New opportunity just announced. Don’t wait.
Invest Now
Brain Scientific Is Making The Next Generation of Teleneurology Possible

Rapidly aging population with increasing neurological care needs is creating a acute neurologist shortfall. In the US, 20 states have fewer than 10 neurologists per 10,000 patients (these areas are called ‘neurology deserts’).

img
The solution is our Neuro-Tech ecosystem which consists of:
  • A disposable, easy to apply, & disposable neuro-cap
  • A portable, wireless EEG amplifier – Neuro EEG
  • A secure cloud for data transfer and storage
  • An AI powered analysis platform
  • Teleneurology network of providers

Thanks to Brain Scientific, hospitals can easily perform EEG tests and upload the data to the cloud, after which Neurologists anywhere in the world can evaluate the test results, provide diagnosis from anywhere in the world, and direct the most appropriate courses of treatment in a timely manner.

Neurological disorders are increasingly recognized as major causes of death and disability worldwide.

More than 50 million people have epilepsy worldwide.

“it is estimated that this number will almost double” – WORLD HEALTH ORGANIZATION, 2020)

Our Mission
img
Products are in market and adoption is growing.
img
Brain Scientific’s mission is to develop algorithms to detect neurological disorders, including epilepsy, memory dementia, and pre-Alzheimer’s diagnosis.
img
Horizontal expansion within existing and established channels as well as penetration into new verticals is occurring (clinical, emergency, educational, etc.).
img
Efficacy is demonstrated by great reviews.
img
Dr. John Gaitanis
Chief of Pediatric Neurology at Tufts Medical Center:
quote img
With Brain Scientific EEG technology, a telemedicine physician could ask the emergency room staff to start the EEG, and they can read it in real-time
Dr. Gaitanis is a medical advisor of Brain Scientific
Offered Solutions
img

Brain Scientific has developed two EEG devices to streamline EEG application and di-agnosis: NeuroCap, a disposable EEG headset with 22 pre-gelled electrodes following the international 10–20 system, and NeuroEEG, a portable wireless EEG amplifier that is smaller than a deck of playing cards. NeuroCap can be applied by any clinical staff in less than 5 minutes, and the 16 channel NeuroEEG amplifier provides the same quality as traditional bulky EEG equipment.

  • NeuroCap requires no upfront cost; hospitals pay-per-patient
  • NeuroCap eliminates the need for a salaried EEG technician- any clinical staff (medical assistans, nurses) can run an EEG test 24/7 with the NeuroCap.
  • NeuroCap is compatible with 3rd party amplifiers
  • NeuroCap setup is time is approximately 5 minutes
  • NeuroCap is disposable and eliminates the risk of hospital-acquired infections (HAI)
  • NeuroCap enables teleneurology, allowing neurologists from a central location to view an EEG recorder anywhere in the world
  • NeuroCap is portable, wireless, and miniature amplifier that fits in the palm of your hand
Summary

NeuroCap and NeuroEEG are positioned to disrupt the otherwise overpriced and under-supplied EEG market with economic and disposable substitutes that permit any medical professional in any setting to diagnose patients remotely within minutes

img
Market Demand

The brain monitoring industry is composed of smaller markets that aim to understand, diagnose, treat, and cure mental conditions. These emerging industries account for a majority of the growth in the brain monitoring industry, and drive the need for improved brain monitoring technology.

Alzheimer’s disease
5 MILLION
Traumatic Brain Injury
2.5 MILLION
Depression
264 MILLION
Epilepsy
50 MILLION
ADHD
6.1 MILLION
Stroke
795,000 (PER YEAR)
Sleep disorders
50-70 MILLION
Dementia
50 MILLION
Migraine
30 MILLION
Invest Now
Epilepsy

Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.

Nearly 80% of people with epilepsy live in low- and middle-income countries. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.

Alzheimer’s

Someone in the world develops dementia every 3 seconds

It is estimated that globally there are 47.5 million people with dementia, with 7.7 million new cases every year. Alzheimer’s disease is the most common cause of dementia and may contribute to 60–70% of cases.

About 1% of Americans have some form of epilepsy, and nearly 4% (1 in 26) will develop epilepsy at some point in their lives.

The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson’s disease, and cerebral palsy combined.

img
Why invest in Brain Scientific
  • We developed two EEG devices to streamline EEG application and diagnosis
  • NeuroCap, a disposable EEG headset with 22 pre-gelled electrodes following the international 10–20 system, and NeuroEEG, a portable wireless EEG amplifier that is smaller than a deck of playing cards.
  • Brain Scientific’s project on graphene EEG electrodes was chosen by Epilepsy Foundation for 2020 Shark Tank Competition Five Finalists
  • Brain Scientific has received FDA 510(k) clearance for NeuroCap and NeuroEEG in 2018
  • Successful early adopters program for NeuroCap and NeuroEEG (2018—2019)
  • Partnered with industry leaders in EEG manufacturing and distributors to service national and global EEG market in progress
  • In 2018—2019, Brain Scientific has presented the company’s technology and devices at international and American conferences and trade shows including American Epilepsy Society (AES) Annual meetings, ASET, ACNS to very warm receptions and new partnership opportunities.
img
News
Dec 17, 2020
Brain Scientific To Enter the U.S. Pediatric Market with NeuroCap™ for Children

NeuroCap™, will now be available to the pediatric market across the U.S. The product launch allows Brain Scientific to bring faster, more efficient NeuroCap™, will now be available to the pediatric market across the U.S. The product launch allows Brain Scientific to bring faster, more efficient

Read more
Dec 15, 2020
Brain Scientific Announces Regulation A+ Offering

Brain Scientific’s Regulation A+ will allow the Company to sell units at $9 each, with a minimum investment of $500. The units consi…

Read more
Dec 2, 2020
Brain Scientific Files Patent Application For Long-Term Monitoring EEG Cap

During EEG testing electrodes are put to the person’s head by either a cap application or placement of each electrode. The latter metho…

Read more
All news
Product Roadmap

We are constantly working on enhancements to address new, growing markets as well as to continuously innovate and improve. We are focusing on developing extensions to address pediatric applications and long-term monitoring.

img
Routine EGG
New product for Routine market: NeuroCap-8 (with 8 channels)
img
Pediatric EGG Caps
New product for Routine market: NeuroCap-8 Pediatric
img
Long-Term Monitoring
New products for LTM market (24+ hours): NeuroCap-8 Adult, NeuroCap-19 Adult, NeuroCap-8 Pediatric, NeuroEEG Amplifier(24 channels
img
Artificial Intelligence
New products for AI market: Brain E-Tattoo, Brain AI: Neutral Network enabled predictive capabilities for brain health
img
This investment is speculative, liquid, and involves a high degree of risk, including the possible loss of your entire investment. For risks relating to this offering, and the Offering Statement dated December 14, 2020, see the Subscription Agreement for this offering.
Stock Information
Corporate Governance
Baruch Goldstein
Co-Founder & Executive Chairman

Dr. Baruch Goldstein has over two decades of experience in neuro-net informatics, brain image recognition and processing, artificial intelligence and management of robotic systems. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital to develop innovative companies and startups in diverse industries. He has built a suite of first-to-market companies as a technology-oriented leader, including RYAH MedTech, Brain Scientific, GrapheneCA, E- Forex and Intelligent Video Systems. Goldstein is also the Co-Founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Nikolay Kukekov
Co-Founder & Executive Chairman

Nickolay V Kukekov, Ph.D. is a Partner at HRA Capital. Prior to forming HRA Capital, Dr. Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research and, prior to that, was a Co-founder of the Healthcare Investment Banking group at Gilford Securities. Prior to joining Gilford, Dr. Kukekov was a Managing Director at Paramount BioCapital, where he ran the advisory, M&A and capital raising services for in-house private and public portfolio companies. Before that, he was a senior healthcare investment banker at Rodman & Renshaw. His scientific background includes a bachelor degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder and a Ph.D. in Neuroscience from Columbia University, College of Physicians and Surgeons in New York. Dr. Kukekov holds a number of research scholarship awards and peer review publications.

img
Download Investor Presentation

Nearly 80% of people with epilepsy live in low- and middle-income countries. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.

Download
Have questions?

Please Schedule a Call With Our Investor Relations Manager

Schedule meeting
Download investor presentation
To get a presentation fill out the form
Thank you. Please check your email to view the Investor Presentation.
Ok